ADMA Biologics, Inc. (ADMA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.4000 |
| Open | 2.3500 |
| Bid | 2.4000 x 28000 |
| Ask | 2.4700 x 21500 |
| Day's Range | 2.3500 - 2.4700 |
| 52 Week Range | 1.0100 - 2.4800 |
| Volume | |
| Avg. Volume | 2,604,825 |
| Market Cap | 481.075M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4900 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADMA
Related Research
- ADMA Biologics IncAnalyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. The company offers contract manufacturing services to pharmaceutical companies. The Hillrom transaction has added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's 2021 revenue came from more digitally connected offerings like its smart beds and Voalte medical communications app.RatingFair ValueEconomic Moat20 days agoMorningstar
- Motley Fool
Why ADMA Biologics Stock Triumphed on Thursday
ADMA Biologics (NASDAQ: ADMA), typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. ADMA attracted a degree of renown in 2020 after its convalescent plasma won Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) to fight COVID. As for the bottom line, ADMA booked a net loss of nearly $14 million ($0.07 per share).
- Zacks
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA)
